Jaguar Health signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group for Venture Life’s FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market. Gelclair is a clinically proven, convenient, and easy to use gel that provides rapid and long-lasting pain relief and improves the ability of oral mucositis patients to eat, drink, swallow, speak and sleep. Gelclair also reduces the need to use parenteral feeding or opiate analgesics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health’s Strategic Moves to Regain Nasdaq Compliance
- Jaguar Health says topline results for trial of crofelemer are ‘forthcoming’
- Jaguar Health granted extension to regain Nasdaq compliance
- Jaguar Health reports 2023 EPS ($1.79) vs. ($36.18) last year